Market brief
Polish Biotech & Pharma Landscape 2026: Warsaw, Wroclaw, Krakow
Poland holds the largest biotech and pharma operator count in Central and Eastern Europe in the directory, with 39 operators across Warsaw, Wroclaw, Krakow, Łódź, Gdańsk, Lublin, Poznań, and smaller sites. Warsaw concentrates national pharma manufacturing (Polpharma, Bioton, Polfa Tarchomin, Adamed), the regulator (URPL), and supporting supply-chain anchors (Thermo Fisher Supply Warsaw, World Courier Poland). Wroclaw operates the Polish innovation-biotech belt — Captor Therapeutics, Pure Biologics, Genomtec, Hemolens, Biotts, Bioavlee, Bioceltix — many sited at Wroclaw Technology Park. Krakow hosts the discovery cluster with Selvita, Ryvu Therapeutics, intoDNA, and Diagnostyka, supported by the Jagiellonian Centre of Innovation. Mabion (Łódź) and Rezon Bio (Gdańsk / Warsaw) add antibody and biosimilar CDMO capacity. For sponsors looking at a Central European biotech footprint in 2026, Poland is the largest single-country inventory the directory surfaces.
Summary
Key findings
Poland holds 39 operators in the directory — the largest single-country inventory after Germany (57) and Sweden (43) — across therapeutics, manufacturing, CDMO, CRO, diagnostics, and infrastructure.
Warsaw concentrates national pharma manufacturing (Polpharma group, Bioton, Polfa Tarchomin, Adamed headquartered or sited in Warsaw or nearby) alongside the Polish regulator URPL and pan-European CRO operations (ICON Poland, Medpace Poland, Pratia Poland).
Wroclaw is Poland’s innovation-biotech belt, with Captor Therapeutics, Pure Biologics, Bioceltix, Genomtec, Hemolens Diagnostics, Biotts, and Bioavlee operating out of Wroclaw Technology Park and the wider innovation ecosystem.
Krakow operates the Polish drug-discovery cluster — Selvita (discovery, biology, DMPK, development services), Ryvu Therapeutics (oncology pipeline), intoDNA and Diagnostyka in diagnostics — supported by Jagiellonian Centre of Innovation.
Numbers
Quick numbers
Analysis
Warsaw: pharma manufacturing + regulator + supply anchors
Warsaw is the Polish capital’s pharma-first centre of gravity. The Polpharma group (Polpharma Starogard Gdański plus Rezon Bio in Gdańsk / Warsaw) sits behind one of Poland’s larger domestic pharmaceutical manufacturers and a biologics CDMO arm. Bioton (Warsaw) operates as a Polish insulin and biosimilar manufacturer. Polfa Tarchomin (Warsaw) is a long-running national pharma manufacturer. Adamed Pharma (Pienkow, near Warsaw) is a diversified pharmaceutical manufacturer. Around these manufacturers, Warsaw also hosts the Polish drug regulator URPL (Office for Registration of Medicinal Products), pan-European CRO operations (ICON Poland, Medpace Poland, Pratia Poland), clinical-stage biotechs (Molecure, ExPLoRNA Therapeutics, BioResearch Pharma, Scope Fluidics in diagnostics, Genomed in genomics), and the three pharmaceutical supply-chain anchors (Thermo Fisher Supply Warsaw, Avantor / VWR Poland in Gdańsk, World Courier Poland). For a Polish pharma, regulatory, or clinical-services engagement, Warsaw is the highest operator-count entry point in the directory.
Analysis
Wroclaw: the Polish innovation-biotech belt
Wroclaw concentrates the Polish innovation-biotech layer. Captor Therapeutics runs a drug-discovery programme focused on targeted protein degradation. Pure Biologics develops antibody and aptamer therapeutics. Bioceltix operates veterinary stem-cell therapeutics at commercial scale. Genomtec, Hemolens Diagnostics, and Bioavlee develop molecular and rapid diagnostic platforms. Biotts works on drug-delivery technology. Wroclaw Technology Park and the wider innovation ecosystem provide the cluster context. For sponsors searching for Polish biotech innovation beyond pharma manufacturing, Wroclaw is the highest operator count per city the directory surfaces outside Warsaw.
Analysis
Krakow: discovery and diagnostics cluster
Krakow concentrates the Polish drug-discovery cluster. Selvita operates a CEE-based contract research organisation for medicinal chemistry, biology, and DMPK, with development-services capacity downstream and a listed parent in Warsaw. Ryvu Therapeutics runs a clinical-stage oncology pipeline and historically shared discovery infrastructure with Selvita. intoDNA develops DNA-damage diagnostics, and Diagnostyka S.A. operates a national laboratory-diagnostics network. Jagiellonian Centre of Innovation (JCI) provides life-science park infrastructure around Jagiellonian University Medical College. For sponsors needing Polish drug-discovery services or early-stage therapeutics partners, Krakow is the discovery-layer equivalent of Warsaw’s manufacturing concentration.
Analysis
Łódź + Gdańsk: the CDMO and clinical-biotech adjunct
Outside the three main cities, Poland holds several regional anchors. Mabion (Łódź) runs antibody biosimilar and originator CDMO services at commercial scope. Bionanopark (Łódź) provides nanotechnology and biotech incubation infrastructure. Gdańsk hosts Human Biome Institute (microbiome therapeutics) and PolTREG (regulatory T-cell therapeutics), plus the Polpharma-group Rezon Bio biologics CDMO (Gdańsk / Warsaw). Lublin adds BioMaxima (diagnostics) and Synthaverse (pharmaceutical manufacturing). Poznań holds Pikralida (therapeutics). These regional entries fill specific gaps in the Polish biotech picture that Warsaw / Wroclaw / Krakow do not cover.
Analysis
Poland in the wider European supply chain
Poland sits strategically between German biologics manufacturing (Rentschler, Vetter, IDT Biologika, AGC Biologics Heidelberg) to the west and Baltic CDMO and clinical-services capacity (Northway Biotech, Biomapas) to the north-east. GDP-certified pharmaceutical logistics through the same operators that cover Germany and the Baltics (DHL Life Sciences & Healthcare, Kuehne+Nagel Healthcare, World Courier Poland) tie the Polish biotech layer into the pan-European supply chain without friction. Selvita in Kraków acts as a natural discovery-services bridge between Polish and German operators. For sponsors running multi-country European footprints, Poland is often the midpoint that connects Baltic nearshore capacity with German commercial scale.
Analysis
How to pick a Polish biotech partner in 2026
Four decisions drive selection. First, the scope: national pharma manufacturing (Polpharma group, Bioton, Polfa Tarchomin, Adamed) vs. innovation-biotech (Wroclaw cluster) vs. drug-discovery services (Selvita, Ryvu) vs. CDMO services (Mabion, Rezon Bio, SyVento) vs. CRO (ICON Poland, Medpace Poland, Pratia Poland). Second, the geography: Warsaw for pharma and regulatory engagement, Krakow for discovery and clinical-stage therapeutics, Wroclaw for innovation-biotech, Łódź for CDMO. Third, the modality fit: antibodies and biosimilars (Mabion, Pure Biologics), small-molecule (Celon Pharma, Ryvu Therapeutics), cell and regulatory T-cell therapy (PolTREG, Bioceltix), diagnostics (Wroclaw + Krakow clusters). Fourth, regulatory and clinical-trial readiness: Polish sites are CTIS-submitted and EMA-aligned like any EU member state. The Memel Biotech directory entry for each operator links to the current public disclosures.
What to watch
What to watch next
Selvita and Ryvu Therapeutics pipeline and capacity announcements
Mabion antibody biosimilar commercial-scale progression
Rezon Bio capacity expansion under the Polpharma Biologics umbrella
Wroclaw innovation-biotech cluster scale-up — Captor, Pure Biologics, Genomtec, Bioceltix
EU Biotech Act implementation effect on Polish biomanufacturing funding
FAQ
Frequently asked questions
Is Poland a credible biotech location for 2026 sponsors?
Yes. Poland is an EU member state with CTIS-submitted clinical trial sites, EMA-aligned regulatory pathways, and the largest biotech and pharma operator count in Central and Eastern Europe. Directory inventory: 39 operators across pharma manufacturing, CDMO, CRO, diagnostics, drug discovery, and innovation-biotech. For sponsors building a European footprint, Poland is a practical option that pairs naturally with German manufacturing to the west and Baltic capacity to the north-east.
Where do I go for Polish pharma manufacturing?
Polpharma (Starogard Gdański) operates as one of Poland’s larger domestic pharmaceutical manufacturers and is the parent of Rezon Bio (Gdańsk / Warsaw), which provides biologics CDMO services. Bioton (Warsaw) runs insulin and biosimilar manufacturing. Polfa Tarchomin (Warsaw) is a long-running national pharma manufacturer. Adamed Pharma (Pienkow, near Warsaw) operates as a diversified pharmaceutical manufacturer. Celon Pharma (Łomianki) adds therapeutics manufacturing.
Who runs drug discovery services in Poland?
Selvita in Kraków operates a CEE contract research organisation for medicinal chemistry, biology, and DMPK, with development services downstream. Ryvu Therapeutics (Kraków) runs an internal oncology pipeline and historically shared discovery infrastructure with Selvita. Pure Biologics (Wroclaw) operates antibody and aptamer discovery. Captor Therapeutics (Wroclaw) works on targeted protein degradation discovery.
Can I run clinical trials in Poland?
Yes. Poland operates multi-site clinical trial infrastructure through ICON Poland, Medpace Poland, and Pratia Poland (all in Warsaw), plus domestic pharma manufacturers with trial capacity. As an EU member state, Polish trial sites submit through CTIS under the Clinical Trials Regulation. Urząd Rejestracji Produktów Leczniczych (URPL, Warsaw) is the national regulator.
How does Poland compare to Germany and the Baltics for sponsors?
Germany holds a larger operator count in the directory (57) with heavier biologics manufacturing concentration. The Baltics are smaller but offer EU-internal nearshore CDMO and CRO capacity (17–40 operators per country). Poland sits between them: more drug-discovery and clinical-services coverage than any individual Baltic country, broader operator distribution across multiple cities, and access to German manufacturing via EU-internal GDP logistics. For multi-country European footprints, Poland is often the practical midpoint.
Methodology note
Sources and interpretation
Sources: verified Memel Biotech directory entries for every Polish operator, official company disclosures, Polish public-registry data where applicable, and editorial comparison against German and Baltic directory coverage. The directory entry for each operator links to the authoritative company sources.
Disclaimer
Use limits
This brief is an editorial map of visible Polish biotech and pharma activity in 2026. It does not rank operators or disclose non-public capacity information — sponsors should verify directly with each operator before engagement.
Primary sources
Source list
Related pages
Related directory records
Briefs
Continue through related topics.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.